Serious Adverse Event Reporting for Cosmetics | US FDA MoCRA Compliance Guide

serious adverse event reporting cosmetics, MoCRA adverse event reporting, US FDA cosmetic compliance, cosmetic safety reporting, cosmetic regulatory compliance, Responsible person cosmetics, US FDA consultancy, XPRO America, FDA serious adverse event Reporting guidelines, FDA cosmetic adverse event reporting, MoCRA adverse event reporting, Cosmetic report, Who can report an adverse event (AE), FDA guidance adverse event reporting, FDA Post marketing adverse event Reporting, New cosmetic Regulations, Are SDS required for cosmetics?, What is a serious adverse event FDA?, Do saes need to be reported to the IRB?, Who is required to report adverse events to the FDA?, What three products are excluded from SDS?, What are the FDA regulations for cosmetics?, What are the 4 types of ADRs?, What are grade 1, 2, 3, 4 adverse events?, How is MDR different from MDD?

The Modernization of Cosmetics Regulation Act (MoCRA) has significantly strengthened post-market safety oversight for cosmetic products in the United States. One of the most critical obligations introduced under MoCRA is mandatory serious adverse event reporting to the US FDA.

Cosmetic companies are now legally required to report serious adverse events associated with their products within a specific timeframe. This requirement enhances consumer protection, improves market surveillance, and ensures faster regulatory intervention when safety risks arise.

XPRO America is a professional US FDA Consultancy supporting cosmetic brands, manufacturers, private labelers, and importers with serious adverse event reporting systems and full MoCRA compliance.

What Is a Serious Adverse Event in Cosmetics

A serious adverse event is an undesirable experience associated with the use of a cosmetic product that results in significant health consequences.

Under MoCRA, serious adverse events include:

Death
Life-threatening experience
Inpatient hospitalization
Persistent or significant disability or incapacity
Congenital anomaly or birth defect
Medical or surgical intervention to prevent any of the above outcomes

Any event meeting these criteria must be reported to the US FDA.

Why Serious Adverse Event Reporting Matters

Serious adverse event reporting allows the US FDA to:

Identify emerging safety risks
Monitor product performance
Take enforcement action when necessary
Protect public health

For cosmetic companies, compliance demonstrates commitment to safety and regulatory responsibility.

Who Is Responsible for Reporting

The Responsible Person (as defined under MoCRA) must submit serious adverse event reports to the US FDA.

The Responsible Person is the manufacturer, packer, or distributor whose name appears on the product label.

Foreign companies must still designate a Responsible Person for products sold in the US.

Reporting Timeline

Serious adverse events must be reported to the US FDA within 15 business days of receipt of the information.

If new medical information becomes available after the initial report, a follow-up report must be submitted within 15 business days of receiving the additional information.

Information Required in a Serious Adverse Event Report

A complete report typically includes:

Product name and description
Lot or batch number (if available)
Description of the adverse event
Outcome of the event
Reporter contact information
Responsible Person contact details

Accuracy and completeness are essential.

XPRO America assists in preparing and validating adverse event reports.

Recordkeeping Requirements

Cosmetic companies must maintain records of:

All adverse events (serious and non-serious)
Supporting documentation
Correspondence related to investigations

Records must be retained for six years and be accessible for US FDA inspection.

Relationship Between Adverse Event Reporting and Recalls

If the US FDA determines that a cosmetic product presents a serious risk to public health, MoCRA gives the agency authority to mandate a recall.

Proper and timely adverse event reporting helps companies demonstrate regulatory cooperation and may reduce enforcement severity.

Common Compliance Pitfalls

Failure to recognize a serious adverse event
Missing reporting deadlines
Incomplete reports
Poor documentation systems
Lack of internal procedures

These issues increase enforcement risk.

Best Practices for Adverse Event Compliance

Establish written adverse event SOPs
Train staff on event identification
Maintain centralized reporting logs
Conduct periodic compliance audits
Partner with an experienced US FDA Consultancy

XPRO America implements customized adverse event reporting systems.

How XPRO America Supports Serious Adverse Event Reporting

XPRO America operates as a trusted US FDA Consultancy offering:

Adverse event reporting procedures
Report preparation and submission
Follow-up reporting management
Recordkeeping system setup
Regulatory correspondence support

For professional assistance with serious adverse event reporting compliance, contact support@xproamerica.com.

Final Thoughts

Serious adverse event reporting for cosmetics is a core MoCRA compliance requirement and a critical component of post-market safety surveillance.

With expert guidance from XPRO America, cosmetic companies can meet US FDA reporting obligations confidently while maintaining strong consumer safety standards.

Serious Adverse Event Reporting for Cosmetics: US FDA MoCRA Compliance Explained